<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04706000</url>
  </required_header>
  <id_info>
    <org_study_id>03.09.20-08/01</org_study_id>
    <nct_id>NCT04706000</nct_id>
  </id_info>
  <brief_title>Autophagy Markers in Endometrial Polyps</brief_title>
  <official_title>Investigation of Autophagy Markers in Endometrial Polyps</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Muğla Sıtkı Koçman University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Muğla Sıtkı Koçman University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this research is to evaluate autophagy markers in patients with endometrial polyps&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Endometrial polyp are benign formations that are frequently encountered in gynecology&#xD;
      practice and have malignant potential. It may be asymptomatic in the clinic or may present&#xD;
      with abnormal uterine bleeding. Although its pathophysiology has not been clearly revealed,&#xD;
      there are many studies in the literature about it. However, the autophagy pathway emerges as&#xD;
      a subject that has never been evaluated. In this study, the investigators would like to&#xD;
      prospectively evaluate Beclin 1, LC3A / B and p62 markers in the autophagy pathway in&#xD;
      endometrial polyp tissue samples by immunohistochemistry and reveal their importance.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">January 8, 2021</start_date>
  <completion_date type="Anticipated">February 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 8, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>autophagy marker</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Beclin 1 gene level</description>
  </primary_outcome>
  <primary_outcome>
    <measure>autophagy marker</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>LC3II gene level</description>
  </primary_outcome>
  <primary_outcome>
    <measure>autophagy marker</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>p62 gene level</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Endometrial Polyp</condition>
  <condition>Autophagy</condition>
  <arm_group>
    <arm_group_label>Study group</arm_group_label>
    <description>endometrial polyp</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <description>normal endometrium</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Beclin 1 gene</intervention_name>
    <description>The determination of Beclin 1, LC3-II and p62 genes, which are evaluated by immunohistochemistry, at the protein level will be done by ELISA method in MSKU Medical Faculty Medical Biology Laboratory.</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Study group</arm_group_label>
    <other_name>LC3-II gene</other_name>
    <other_name>p62 gene</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with histopathologically proven endometrial polyp and healthy controls&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients over 35 years of age with a histopathologically confirmed diagnosis of&#xD;
             endometrial polyp&#xD;
&#xD;
          -  patients over the age of 35 whose histopathologically reported normal endometrial&#xD;
             biopsy results.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Are under the age of 35,&#xD;
&#xD;
          -  those with cognitive dysfunction,&#xD;
&#xD;
          -  diagnosed with any type of cancer&#xD;
&#xD;
          -  who are under treatment for cancer,&#xD;
&#xD;
          -  diabetes mellitus,&#xD;
&#xD;
          -  hypertension,&#xD;
&#xD;
          -  endometriosis,&#xD;
&#xD;
          -  adenomyosis,&#xD;
&#xD;
          -  chronic endometritis,&#xD;
&#xD;
          -  have an acute or chronic illness,&#xD;
&#xD;
          -  patients who have smoked and used alcohol in the last 10 years&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>endometrial polyp</gender_description>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Burak SEZGİN, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Muğla Sıtkı Koçman University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Burak SEZGİN, MD</last_name>
    <phone>+905332347655</phone>
    <email>buraksezgin@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mugla Sıtkı Kocman University Faculty of Medicine</name>
      <address>
        <city>Muğla</city>
        <zip>48000</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Burak Sezgin, Dr</last_name>
      <phone>+905332347655</phone>
      <email>buraksezgin@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <reference>
    <citation>Zhang J. Teaching the basics of autophagy and mitophagy to redox biologists--mechanisms and experimental approaches. Redox Biol. 2015;4:242-59. doi: 10.1016/j.redox.2015.01.003. Epub 2015 Jan 13. Review.</citation>
    <PMID>25618581</PMID>
  </reference>
  <reference>
    <citation>Zhan L, Yao S, Sun S, Su Q, Li J, Wei B. NLRC5 and autophagy combined as possible predictors in patients with endometriosis. Fertil Steril. 2018 Oct;110(5):949-956. doi: 10.1016/j.fertnstert.2018.06.028.</citation>
    <PMID>30316442</PMID>
  </reference>
  <reference>
    <citation>Xie Z, Klionsky DJ. Autophagosome formation: core machinery and adaptations. Nat Cell Biol. 2007 Oct;9(10):1102-9. Review.</citation>
    <PMID>17909521</PMID>
  </reference>
  <reference>
    <citation>Wong M, Crnobrnja B, Liberale V, Dharmarajah K, Widschwendter M, Jurkovic D. The natural history of endometrial polyps. Hum Reprod. 2017 Feb;32(2):340-345. doi: 10.1093/humrep/dew307. Epub 2016 Dec 18.</citation>
    <PMID>27994000</PMID>
  </reference>
  <results_reference>
    <citation>Zhang L, Liu Y, Xu Y, Wu H, Wei Z, Cao Y. The expression of the autophagy gene beclin-1 mRNA and protein in ectopic and eutopic endometrium of patients with endometriosis. Int J Fertil Steril. 2015 Jan-Mar;8(4):429-36. Epub 2015 Feb 7.</citation>
    <PMID>25780525</PMID>
  </results_reference>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 8, 2021</study_first_submitted>
  <study_first_submitted_qc>January 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 12, 2021</study_first_posted>
  <last_update_submitted>January 11, 2021</last_update_submitted>
  <last_update_submitted_qc>January 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Muğla Sıtkı Koçman University</investigator_affiliation>
    <investigator_full_name>Burak Sezgin</investigator_full_name>
    <investigator_title>Principal investigator M.D. Burak Sezgin</investigator_title>
  </responsible_party>
  <keyword>polyp</keyword>
  <keyword>endometrium</keyword>
  <keyword>beclin 1</keyword>
  <keyword>LC3</keyword>
  <keyword>p62</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Neoplasms</mesh_term>
    <mesh_term>Polyps</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>When we conducted the study, we will plan to make individual participant data (IPD) available to other researchers.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

